U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444684) titled 'A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum' on Feb. 26.
Brief Summary: This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
Study Start Date: March 05
Study Type: INTERVENTIONAL
Condition:
Pyoderma Gangrenosum
Intervention:
DRUG: SHR-1139 Injection
SHR-1139 injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....